BCEL is set to produce additional data from a phase 1b trial of its antibody ATRC-101 in multiple solid tumor types. Based on previous data, BCEL has refined the patients it enrolls in the trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback